Spero Therapeutics announced on October 29, 2024, that its Phase 2a proof-of-concept study of SPR720 for Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) did not meet its primary endpoint. This determination was based on a planned interim analysis of data from 16 patients.
Following this clinical setback, Spero Therapeutics suspended the development of the oral SPR720 program. The company also announced a significant restructuring of its operations, including a reduction in its workforce by 39%.
This strategic realignment is expected to extend the company's cash runway into mid-2026, with an unaudited cash balance of $76.3 million as of September 30, 2024. The Phase 3 PIVOT-PO trial for tebipenem HBr remains on track for enrollment completion in the second half of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.